Zimmer, Alexandra Nichols, Erin Cimino-Mathews, Ashley Peer, Cody Cao, Liang Lee, Min-Jung Kohn, Elise Annunziata, Christina Lipkowitz, Stanley Trepel, Jane Sharma, Rajni Mikkilineni, Lekha Gatti-Mays, Margaret Figg, William Houston, Nicole Lee, Jung-Min Additional file 4: of A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses Figure S4. Proinflammatory cytokines analysis. Plasma levels of pro-inflammatory cytokines (IFN γ, TNFα, IL 2, IL 6, IL 8 IL 10, and IL 12) were not changed significantly by the treatment. (PPTX 189 kb) Ovarian cancer;Immune checkpoint inhibitor;PARP inhibitor;VEGF inhibition 2019-07-26
    https://springernature.figshare.com/articles/presentation/Additional_file_4_of_A_phase_I_study_of_the_PD-L1_inhibitor_durvalumab_in_combination_with_a_PARP_inhibitor_olaparib_and_a_VEGFR1_3_inhibitor_cediranib_in_recurrent_women_s_cancers_with_biomarker_analyses/9109274
10.6084/m9.figshare.9109274.v1